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ORIGINAL ARTICLE
Greatly reduced risk of EBV reactivation in
rituximab-experienced recipients of alemtuzumab-conditioned
allogeneic HSCT
DM Burns1,2, S Rana2, E Martin3, S Nagra2, J Ward2, H Osman4, AI Bell2, P Moss2,5, NH Russell6, CF Craddock1,2, CP Fox6 and S Chaganti1,2
EBV-associated post-transplant lymphoproliferative disease (PTLD) remains an important complication of allogeneic
haematopoietic stem cell transplantation (allo-HSCT). We retrospectively analysed the incidence and risk factors for EBV reactivation
in 186 adult patients undergoing consecutive allo-HSCT with alemtuzumab T-cell depletion at a single centre. The cumulative
incidence of EBV reactivation was 48% (conﬁdence interval (CI) 41–55%) by 1 year, with an incidence of high-level EBV reactivation
of 18% (CI 13–24%); 8 patients were concurrently diagnosed with PTLD. Amongst patients with high-level reactivation 31/38 (82%)
developed this within only 2 weeks of ﬁrst EBV qPCR positivity. In univariate analysis age⩾ 50 years was associated with
signiﬁcantly increased risk of EBV reactivation (hazard ratio (HR) 1.54, CI 1.02–2.31; P= 0.039). Furthermore, a diagnosis of
non-Hodgkin lymphoma (NHL) was associated with greatly reduced risk of reactivation (HR 0.10, CI 0.03–0.33; P= 0.0001) and this
was conﬁrmed in multivariate testing. Importantly, rituximab therapy within 6 months prior to allo-HSCT was also highly predictive
for lack of EBV reactivation (HR 0.18, CI 0.07–0.48; P= 0.001) although confounding with NHL was apparent. Our data emphasise the
risk of PTLD associated with alemtuzumab. Furthermore, we report the clinically important observation that rituximab, administered
in the peri-transplant period, may provide effective prophylaxis for PTLD.
Bone Marrow Transplantation (2016) 51, 825–832; doi:10.1038/bmt.2016.19; published online 22 February 2016
INTRODUCTION
Post-transplant lymphoproliferative disease (PTLD) remains a
life-threatening complication of allogeneic haematopoietic stem
cell transplant (allo-HSCT).1–3 In this setting, almost all cases arise
from donor-derived B cells, transformed by the ubiquitous double-
stranded DNA gamma-herpesvirus EBV. In healthy individuals, EBV
establishes a lifelong latent infection within resting memory B
cells and is controlled by potent virus-speciﬁc T-cell responses.
However, in the state of T-cell immunocompromise that follows
allo-HSCT, latently infected B cells may exhibit opportunistic
expansion. Viral reactivation may be detected as an increase in the
level of circulating viral genomes, EBV DNAemia, as measured by
EBV-speciﬁc quantitative PCR (EBV qPCR). Established PTLD has
conventionally been associated with high rates of mortality. The
incidence of PTLD arising after allo-HSCT varies signiﬁcantly in
relation to graft T-cell depletion (TCD), ranging from less than 1%
without TCD to more than 10% with TCD in some series.4–16
Other important risk factors include the use of unrelated and/or
HLA-mismatched donors, the occurrence of severe GvHD and
older age.
Of the different methods of TCD in current use, anti-thymocyte
globulin has been associated with substantially elevated rates of
EBV reactivation and PTLD.4,12,14,16 Meanwhile, the anti-CD52
monoclonal Ab Campath is thought to confer a lower incidence of
PTLD, reportedly 0.4–1.3% in initial studies.4,5 Unlike anti-
thymocyte globulin, which selectively depletes T cells, Campath
targets all lymphocytes. Therefore, the risk of disease associated
with Campath may be mitigated by simultaneous depletion of B
cells. However, initial studies examining the risks associated
with Campath involved ﬁrst and second generation rat antibodies
(Campath-1M and -1G). Meanwhile, relatively few studies have
examined the third generation humanised Ab Campath-1H
(alemtuzumab), which has superseded the other Abs in
routine clinical practice.17 Alemtuzumab has a much longer
half-life than Campath-1G (15–21 days, compared with less than
24 h) and causes prolonged delays in the reconstitution of both
general18,19 and EBV-speciﬁc T-cell immunity.20 Consequently,
it might contribute to an increased risk of PTLD compared with
earlier antibodies.
Introduction of the anti-CD20 monoclonal Ab rituximab has
signiﬁcantly improved PTLD-related mortality.21 In particular,
administration of rituximab to individuals who develop EBV
reactivation, pre-empting the development of PTLD, has led to a
marked reduction in mortality relative to historic cohorts.11,22–25
However, there remains marked inter-centre variation in EBV qPCR
methodology and a lack of consensus as to the optimal virus load
thresholds to trigger pre-emptive intervention.26–28 An alternative
strategy for the prevention of PTLD is prophylactic infusion of
donor-derived EBV-speciﬁc cytotoxic T lymphocytes prepared
in vitro.29 Although efﬁcacious, this approach has not been widely
adopted, largely because of the logistical and ﬁnancial burdens
involved. It has also been proposed that peri-transplant rituximab
(delivered shortly before or after transplant) might be an effective
method of prophylaxis.30,31
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To explore these issues, work was undertaken to deﬁne
incidence, kinetics and risk factors for EBV reactivation and PTLD
amongst adult patients undergoing alemtuzumab TCD allo-HSCT
at a major UK transplant centre.
Table 1. Patient characteristics
N %
Age
Median years (range) 51 (17–71)
Sex
Male 120 65
Female 66 35
Diagnosis
AML/MDS 98 53
NHL 29 16
ALL 18 10
HL 11 6
CLL 11 6
MPD 11 6
Other 8 4
Donor
Unrelated 127 68
Sibling 59 32
HLA mismatches
None 151 81
⩾ 1 Ags 35 19
Stem cell source
PBSC 186 100
Intensity
Reduced intensity 149 80
Myeloablative 37 20
Conditioning
Flu Mel 129 69
Cy TBI 37 20
BEAM +/− Flu 15 8
Other 5 3
Acute GvHD
Grade⩾ II 66 35
Abbreviations: ALL= acute lymphocytic leukaemia; AML= acute
myeloid leukaemia; BEAM= carmustine with etoposide, cytarabine and
melphalan; CLL= chronic lymphocytic leukaemia; Cy= cyclophosphamide;
Flu= ﬂudarabine; GvHD= graft versus host disease; HLA=human leuko-
cyte antigen; HL=Hodgkin lymphoma; MDS=myelodysplastic syndrome;
Mel=melphalan; MPD=myeloproliferative disorder; NHL=non-Hodgkin
lymphoma; PBSC=peripheral blood stem cells; TBI= total body irradiation.
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Figure 1. Incidence of EBV reactivation after alemtuzumab TCD
Allo-HSCT. The cumulative incidence of EBV DNAemia following
allo-HSCT was calculated taking the competing risk of death into
account. The plots display incidence for 186 patients who received
TCD with alemtuzumab. (a) Incidence of EBV qPCR positivity, deﬁned
as a single result ⩾ 500 genomes/mL. (b) Incidence of high-level EBV
DNAemia, deﬁned as a single result ⩾ 20 000 genomes/mL.
Table 2. Patients with PTLD after allo-HSCT
No. Diagnosis Age,
years
Sex Regimen Donor First EBV
DNAemia,
day
First EBV
DNAemia,
copies/mL
High EBV
DNAemia,
day
High EBV
DNAemia,
copies/mL
Peak EBV
DNAemia,
copies/mL
PTLD
diagnosed,
day
Stage Extranodal
disease
Histologya Outcome,
cause of
death
Follow-
up,
months
1 AML 34 M Cy TBI MUD 119 71 000 119 71 000 4 346 790 135 IIIB — — Dead, relapse 13
2 ALL 63 M Flu Mel Sib 71 193 324 71 193 324 2 704 380 78 IIIB — — Alive 29
3 AML 57 M Flu Mel MUD 119 81 686 119 81 686 2 150 650 128 IVB CNS DLBCL Dead, PTLD 5
4 HL 43 M Flu Mel MUD 70 5412 84 36 407 57 039 85 IIIA — — Dead, PTLD 8
5 AML 29 F Cy TBI MUD 71 33 664 71 33 664 329 542 78 IIIA — — Alive 34
6 MDS 64 M Flu Mel MUD 49 712 63 233 774 1 805 490 65 IVB Bowel Polymorphic Dead, PTLD 6
7 AML 57 M Flu Mel Sib 84 6405 91 94 945 94 945 92 IIB — Polymorphic Dead, relapse 15
8 ALL 42 F Flu Mel MUD 64 7564 70 494 794 494 794 77 IIIA — — Alive 13
Abbreviations: ALL= acute lymphocytic leukaemia; AML= acute myeloid leukaemia; BEAM= carmustine with etoposide, cytarabine and melphalan;
CLL= chronic lymphocytic leukaemia; CNS= central nervous system; Cy= cyclophosphamide; DLBCL=diffuse large B-cell lymphoma; Flu= ﬂudarabine;
GvHD= graft versus host disease; HLA=human leukocyte antigen; HL=Hodgkin lymphoma; HSCT=haematopoietic stem cell transplantation;
MDS=myelodysplastic syndrome; MUD=HLA-matched unrelated donor; Mel=melphalan; MPD=myeloproliferative disorder; NHL= non-Hodgkin
lymphoma; PBSC=peripheral blood stem cells; Sib=HLA-matched sibling; TBI= total body irradiation. aBiopsy material was obtained from three patients
—all other patients were diagnosed with probable PTLD.
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SUBJECTS AND METHODS
This retrospective study examined adult patients undergoing consecutive
TCD allo-HSCT at University Hospital Birmingham between May 2009 and
September 2012. The study was registered with University Hospital
Birmingham Research and Development department, and participants
provided written consent for clinical data collection. All patients received
myeloablative or reduced-intensity conditioning according to institutional
protocols, followed by PBSC graft infusion. TCD was carried out with in vivo
alemtuzumab, comprising 10 mg daily intravenously from day -7 to day -3
before stem cell infusion. GvHD prophylaxis comprised cyclosporine, with
or without methotrexate, or mycophenolate mofetil. All patients received
aciclovir prophylaxis for a minimum of 3 months following transplant.
Patients were monitored using EBV qPCR whole blood assay of the EBV
polymerase gene BALF5.32 EBV qPCR testing was scheduled every
1–2 weeks for the ﬁrst 6 months post transplant and intermittently
thereafter. EBV reactivation was deﬁned as a single positive EBV qPCR result
exceeding the assay limit of sensitivity of 500 genomes/mL. High-level EBV
reactivation was deﬁned as a single result ⩾ 20 000 genomes/mL—a locally
determined threshold selected on the basis of prior experience of the
assay performed in this clinical setting. Patients exceeding the high-level
EBV threshold were assessed for possible PTLD and received pre-emptive
treatment with up to 4 weekly infusions of rituximab 375 mg/m2. Cases of
PTLD were diagnosed in accordance with published deﬁnitions for biopsy-
proven or probable disease arising after allo-HSCT, the latter including
radiologic evidence of disease in association with EBV DNAemia.33
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Figure 2. Kinetics of EBV reactivation after allo-HSCT. (a) Interval from transplant to ﬁrst EBV qPCR-positive test, ⩾ 500 genomes/mL. (b) Interval
from transplant to high-level EBV DNAemia, ⩾ 20 000 copies/mL. (c) Interval from ﬁrst EBV qPCR-positive test to high-level EBV DNAemia. The
proportion of patients exhibiting high-level EBV DNAemia within 2 weeks of initial EBV qPCR positivity is indicated.
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Cumulative incidence of EBV reactivation was estimated taking the
competing risk of death into account. Cumulative incidence curves were
compared using the Log Rank test. Univariate and multivariate analysis of
risk factors for EBV reactivation were performed using Cox proportional
hazards modelling. Acute GvHD was treated as a time-dependent
covariate. The effects of pre-transplant or post-transplant (pre-emptive)
rituximab therapy on overall survival or non-relapse mortality was analysed
using Cox testing, considering post transplant rituximab as a time-
dependent covariate. All analyses were carried out in Stata 12.
RESULTS
Incidence and kinetics of EBV reactivation and PTLD
This study includes 186 adult patients undergoing ﬁrst allo-HSCT
with alemtuzumab TCD at University Hospital Birmingham, UK.
Median follow-up was 28 months. Overall survival was 72% at
1 year post transplant, with non-relapse mortality of 2.9% at
100 days and 11.5% at 1 year. Patient characteristics are
summarised in Table 1. Monitoring revealed a cumulative
incidence of EBV reactivation (⩾500 genomes/mL) of 48%
(95% conﬁdence interval (CI) 41–55%) at 1 year (Figure 1a).
Furthermore, the cumulative incidence of high-level EBV reactiva-
tion (⩾20 000 genomes/mL) was 18% (CI 13–24%; Figure 1b).
In total, 38 patients developed high-level EBV reactivation.
Of these, eight were concurrently diagnosed with PTLD
(Table 2). The median interval between ﬁrst EBV load ⩾ 20 000
copies/mL and radiographically documented disease (comprising
computed tomography and/or positron emission tomography–
computed tomography imaging in all cases) was only 7 days
(range 1–16 days). Five (63%) patients had B symptoms
documented at presentation and 7/8 (88%) had stage ⩾ 3 disease.
The kinetics of post-transplant EBV reactivation are summarised
in Figure 2. Most reactivations occurred between 8 and 16 weeks
after transplant. No cases of high-level EBV reactivation occurred
in the ﬁrst 8 weeks. However, late high-level reactivations,
occurring more than a year after transplant, were still observed
in 4/38 (11%) patients. Importantly, analysis of the time interval
from initial EBV qPCR positivity to high-level EBV reactivation
(Figure 2c) revealed that 13/38 (34%) patients already exhibited
high-level reactivation at ﬁrst EBV qPCR positivity, and a further 18
patients developed high-level reactivation within 2 weeks of this.
As such, a total of 31/38 (82%) patients developed high-level EBV
reactivation within only 2 weeks of ﬁrst EBV qPCR positivity.
Pre-emptive management
All 38 patients with high-level EBV reactivation, including 8
diagnosed with PTLD, were treated pre-emptively with up to
4 weekly infusions of rituximab (Figure 3). Of these, all 30 without
evidence of PTLD, and 5/8 (63%) with PTLD, responded—deﬁned
as sustained resolution of EBV loads to undetectable levels and
complete radiological remission of disease where present. Three
patients with PTLD showed refractoriness to rituximab, all of
whom died from progressive disease despite further treatment
including CHOP chemotherapy in two cases (Supplementary
Figure S1).
As some authors have raised concerns about the safety of
rituximab following allo-HSCT,34,35 the impact of pre-emptive
rituximab on survival was analysed; three patients who died from
PTLD were excluded from this analysis to eliminate the effect of
PTLD-related mortality. This revealed no signiﬁcant deleterious
effect from pre-emptive rituximab on overall survival (hazard ratio
(HR) 1.41, CI 0.79–2.51; P= 0.239) or non-relapse mortality (HR 1.57,
CI 0.62–3.94; P= 0.338).
Factors predicting for EBV reactivation
Baseline predictors of EBV reactivation were analysed using
univariate Cox regression (Table 3 and Figure 4). This revealed
patients aged ⩾ 50 years to be at signiﬁcantly increased risk
(HR 1.54, CI 1.02–2.31; P= 0.039) of viral reactivation. Furthermore,
although the intensity of transplant conditioning was not
signiﬁcantly predictive overall, Flu Mel conditioning was
associated with increased risk relative to Cy TBI (HR 0.63,
CI 0.37–1.08; P= 0.092, borderline signiﬁcance). Notably, unrelated
donors or HLA-Ag mismatching were not identiﬁed as risk factors.
Meanwhile, a signiﬁcant association between acute GvHD grade
⩾ II and risk of high-level EBV reactivation was also observed
(HR 2.51, CI 1.10–5.70; P= 0.028), although other variables were
not predictive for high-level EBV reactivation in this relatively small
dataset.
Importantly, a diagnosis of non-Hodgkin lymphoma (NHL) was
associated with a highly signiﬁcant reduction in the risk of EBV
reactivation (HR 0.10, CI 0.03–0.33; P= 0.0001). Thus, of 29 patients
with NHL, only 3 developed EBV qPCR positivity (on days 57, 380
and 565). Furthermore, no cases of high-level EBV reactivation
were observed for those with NHL in the 2 years after transplant.
This was apparent despite equivalent frequency and duration of
EBV monitoring in comparison with other patients. Notably, the
markedly reduced risk of EBV reactivation observed for patients
with NHL was not similarly noted for those with Hodgkin
lymphoma; 6/11 (55%) patients with Hodgkin lymphoma
exhibited EBV qPCR positivity, including 5 cases of high-level
EBV DNAemia.
To establish whether the lack of EBV reactivation observed
amongst patients with NHL was independent of other
baseline factors, multivariate testing was performed using a Cox
proportional hazards model including baseline factors age,
diagnosis and transplant conditioning (Table 4). In this analysis,
a diagnosis of NHL remained highly predictive for lack of EBV
reactivation (HR 0.18, CI 0.05–0.57; P= 0.004).
NR
N = 3
Rituximab
N = 8
CR
N = 5
Rituximab
N = 30
No PTLD
N = 30
CR
N = 30
PTLD
N = 8
High EBV
N = 38
Figure 3. Pre-emptive management of EBV reactivation after allo-
HSCT. All patients with EBV DNAemia ⩾ 20 000 copies/mL were
treated with up to 4 weekly infusions of rituximab 375 mg/m2. The
ﬂowchart summarises outcomes for all treated patients, eight of
whom were concurrently diagnosed with PTLD at initiation of
therapy. Response is deﬁned as complete and sustained resolution
of EBV DNAemia and disease where evident.
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Pre-transplant rituximab
The pre-transplant use of rituximab was examined as a possible
determinant of the highly signiﬁcant reduction in risk of EBV
reactivation observed amongst patients with NHL. Rituximab use
was documented in 28/29 (97%) patients with NHL, with the last
infusion administered a median 3 months (interquartile range
2–5 months) before transplant. Prior rituximab was also recorded
in 10/11 (91%) patients with CLL, although the last infusion of
rituximab was delivered substantially longer before transplant, at
median 15 months (interquartile range 8–26 months). Importantly,
only 1/25 (4%) patients who received rituximab within 6 months
before transplant reactivated EBV in the ﬁrst year—a patient with
CLL who received rituximab 5 months prior to transplant and who
developed high-level EBV reactivation on day 78. In contrast, 7/13
(54%) patients who received rituximab more than 6 months
before transplant developed EBV reactivation, including 2 patients
with high-level EBV reactivation.
In univariate Cox analysis, there was a highly signiﬁcant
association between pre-transplant rituximab therapy and lack
of EBV reactivation, using deﬁnitions of pre-transplant rituximab of
‘at any time’ prior to transplant (HR 0.34, CI 0.18–0.64; P= 0.001) or
‘within 6 months’ prior to transplant (HR 0.18, CI 0.07–0.48;
P= 0.001). These differences did not persist in multivariate testing,
but this analysis was complicated for several reasons. Firstly, there
was strong confounding between diagnostic category and prior
use of rituximab, such that almost all patients with NHL and CLL
received rituximab at some time before transplant. Secondly, it is
unclear what constitutes a biologically appropriate cutoff (months
before transplant) to deﬁne pre-transplant rituximab. Finally, few
patients with NHL reactivated EBV, even if they received rituximab
more than 6 months before transplant, unlike patients with CLL
(Supplementary Table S1).
Regarding the safety of pre-transplant rituximab, testing
revealed no signiﬁcant difference in overall survival for patients
treated with rituximab at any time before transplant (HR 0.75,
CI 0.42–1.33; P= 0.317) or within 6 months before transplant
(HR 0.76, CI 0.38–1.52; P= 0.441). Similarly, no signiﬁcant
differences were seen in non-relapse mortality for rituximab given
at any time before transplant (HR 1.00 CI 0.46–2.18; P= 0.994)
or using a 6 month cutoff (HR 0.95, CI 0.37–2.43; P= 0.907).
An association between pre-transplant rituximab and risk of either
Grade ⩾ I or Grade ⩾ II acute GvHD was not observed.
Table 3. Univariate analysis of risk factors for EBV reactivation after allo-HSCT
EBV ⩾ 500 copies/mL EBV ⩾ 20 000 copies/mL
HR 95% CI P value HR 95% CI P value
Age
⩾ 50 years 1.54 1.02–2.31 0.039 1.54 0.79–3.01 0.206
Sex
Male versus female 1.22 0.80–1.88 0.360 1.45 0.71–2.99 0.311
Diagnosis
AML/MDS 1.00 — Ref 1.00 — Ref
NHL 0.10 0.03–0.33 0.0001 No events — —
ALL 0.80 0.41–1.56 0.513 0.67 0.20–2.22 0.510
HL 0.80 0.34–1.84 0.585 1.84 0.70–4.82 0.213
CLL 1.01 0.48–2.11 0.989 0.93 0.28–3.09 0.908
MPD 0.95 0.43–2.10 0.905 0.30 0.04–2.20 0.236
Other 1.26 0.54–2.93 0.591 0.39 0.05–2.89 0.358
Donor
Sibling versus unrelated 1.24 0.83–1.87 0.291 0.64 0.31–1.32 0.226
HLA mismatches
⩾ 1 Ags 0.93 0.55–1.57 0.794 0.87 0.36–2.09 0.760
Intensity
Myeloablative versus RIC 0.76 0.44–1.29 0.309 0.82 0.34–1.97 0.661
Conditioning
Flu Mel 1.00 — Ref 1.00 — Ref
Cy TBI 0.63 0.37–1.08 0.092 0.69 0.29–1.65 0.404
BEAM+/− Flu No events — — No events — —
Other 0.81 0.25–2.56 0.714 No events — —
Acute GvHD
Grade⩾ II 1.53 0.91–2.57 0.112 2.51 1.10–5.70 0.028
Prior rituximab
Within 6 months 0.18 0.07–0.48 0.001 0.16 0.02–1.17 0.072
At any time 0.34 0.18–0.64 0.001 0.30 0.09–0.98 0.046
Abbreviations: ALL= acute lymphocytic leukaemia; AML= acute myeloid leukaemia; BEAM= carmustine with etoposide, cytarabine and melphalan;
CI= conﬁdence interval; CLL= chronic lymphocytic leukaemia; Cy= cyclophosphamide; Flu= ﬂudarabine; GvHD=graft versus host disease; HLA=human
leukocyte antigen; HL=Hodgkin lymphoma; HR=hazard ratio; HSCT=haematopoietic stem cell transplantation; MDS=myelodysplastic syndrome;
Mel=melphalan; MPD=myeloproliferative disorder; NHL=non-Hodgkin lymphoma; PBSC=peripheral blood stem cells; Ref= reference category;
RIC= reduced-intensity conditioning; TBI= total body irradiation.
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DISCUSSION
To our knowledge, the present study is the largest of its kind to
analyse the incidence, kinetics and risk factors for EBV reactivation
and PTLD amongst alemtuzumab-treated adult patients under-
going allo-HSCT. We report clinically important rates of these
complications, with 48% of individuals exhibiting EBV qPCR
positivity by 1 year post transplant and 18% developing high-
level EBV reactivation. Furthermore, PTLD was diagnosed in eight
patients, giving a crude incidence of 4.3%. This incidence is
noticeably greater than that reported in the study of 111
alemtuzumab-treated patients by Carpenter et al.,11 in which only
0.9% of patients developed PTLD. However, it is apparent
that around a third of patients in the latter study received
alemtuzumab ‘in the bag’ (in which the drug is used to treat the
stem cell graft in vitro before infusion) rather than in vivo; higher
peak concentrations and persistence of alemtuzumab have been
reported when it is used in vivo,36 and this is also associated with
delayed reconstitution of EBV-speciﬁc immunity.20 Notably, the
incidence of PTLD observed for alemtuzumab-treated patients in
the present study remains within the range reported by other
smaller series.6–9
Regarding the kinetics of EBV reactivation, most events
occurred between 2 and 4 months after transplant, but some
cases were documented up to and beyond 12 months. Given this,
it is notable that recent guidelines have advised that patients
undergoing allo-HSCT at high risk of PTLD should be monitored
with EBV qPCR for 3 months post transplant.33 The current study
supports extending this recommendation to 6 months, at least for
alemtuzumab-treated patients. Furthermore, given that greater
than 80% of high-level reactivations occurred within 2 weeks of
initial EBV qPCR positivity, we suggest that particular scrutiny
should be exercised in the ﬁrst few days following initial EBV qPCR
positivity.
Using pre-emptive treatment with rituximab, we observed very
good response rates amongst patients who developed high-level
EBV reactivation. Thus, 35/38 (92%) of patients exhibited complete
resolution of viral DNAemia and disease where present, with no
apparent increase in mortality amongst treated patients. Although
based on a relatively small number of patients, our ﬁndings
support the efﬁcacy and safety of rituximab in this setting.
However, three patients developed rituximab-refractory PTLD and
died from progressive disease despite the use of cytotoxic
chemotherapy. Our experience accords with other reports
showing poor outcomes with chemotherapy in this setting.2,3
In light of this and other data,37 we now aim to treat all patients
who develop rituximab-refractory PTLD following allo-HSCT with
EBV cytotoxic T lymphocytes or donor-lymphocyte infusion, where
practicable.
Analysis of predictors for EBV reactivation revealed that older
age at transplant and the occurrence of acute GvHD were
signiﬁcant risk factors. However, our most striking ﬁnding was a
dramatically reduced incidence of EBV reactivation and PTLD
amongst patients with a diagnosis of NHL. These individuals
exhibited a highly signiﬁcant reduction in the risk of EBV
reactivation in both univariate and multivariate analyses. None
of the 29 patients with NHL exhibited high-level reactivation.
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Figure 4. Incidence of EBV reactivation by diagnosis and prior rituximab exposure. Plots show the cumulative incidence of: (a) EBV qPCR
positivity (⩾500 genomes/mL) in patients with AML/MDS versus NHL, (b) EBV qPCR positivity in patients according to rituximab exposure
within 6 months prior to transplant, (c) high-level EBV DNAemia (⩾20 000 copies/mL) in patients with AML/MDS versus NHL and (d) high-level
EBV DNAemia according to rituximab exposure within 6 months prior to transplant. Cumulative incidence curves are compared with the Log
Rank test.
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Whilst our data should be treated with some caution owing to the
retrospective nature of the study, our observation raises the
possibility that rituximab delivered prior to transplant might
confer a protective effect. In support of this, we found that
patients with HL did frequently experience EBV reactivation—HL is
not routinely treated with rituximab. Furthermore, our observa-
tions are consistent with the anecdotal description by Savani
et al.30 of an absence of EBV reactivation after allo-HSCT in
38 patients who received rituximab prior to, or concurrent with,
transplantation. Although similar ﬁndings have not been reported
in other studies of EBV reactivation and PTLD after allo-HSCT, this
may be because these pre-date the routine use of rituximab for
patients with NHL4,5 or because they have not speciﬁcally
analysed the risks associated with NHL.9,10,12–16
In light of the above, it is possible that rituximab delivered
shortly before (or after) transplant might be a highly effective
alternative to pre-emptive strategies for managing PTLD. At the
very least, rituximab might be used as prophylaxis for high risk
patients, such as those who require anti-thymocyte globulin.
Conceivably, prior rituximab might prevent EBV reactivation by
delaying post transplant B-cell reconstitution. Indeed, it has a
half-life of up to 18 days, with levels remaining detectable in the
serum for up to 3 months after administration, and it is known to
deplete circulating B cells for around 6 months.38 Notably,
van Dorp et al.39 demonstrated a signiﬁcantly reduced rate of
B-cell reconstitution in patients who had received rituximab within
6 months prior to transplant. Alternatively, rituximab might act by
reducing the recipient pre-transplant EBV burden. Interestingly,
the latter supposes that it is predominantly recipient-derived virus
that drives EBV reactivation post allo-HSCT, which might be the
case following reduced-intensity conditioning.
To conclude, in this study we have examined EBV reactivation
and PTLD amongst a large cohort of adult patients undergoing
alemtuzumab TCD allo-HSCT. Importantly, we conﬁrm that
alemtuzumab is a clinically important risk factor for the develop-
ment of PTLD. Furthermore, we observe that the risk of EBV
reactivation appears to be greatly reduced amongst patients with
NHL who have previously been exposed to rituximab. This
suggests that peri-transplant rituximab might be effective
prophylaxis for PTLD arising after allo-HSCT. Our data make a
strong case for prospectively evaluating the role of rituximab in
allograft conditioning.
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